tosedostat

an aminopeptidase inhibitor with antineoplastic activity; structure in first source

Also Known As:

2-(2-(hydroxy(hydroxycarbamoyl)methyl)-4-methylpentanoylamino)-2-phenylethanoic acid cyclopentyl ester; CHR 2797; CHR-2797; CHR2797; Benzeneacetic acid, alpha-(((2R)-2-((1S)-1-hydroxy-2-(hydroxyamino)-2-oxoethyl)-4-methyl-1-oxopentyl)amino)-, cyclopentyl ester, (alphaS)-

Networked: 20 relevant articles (2 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Löwenberg, Bob: 2 articles (02/2021 - 10/2010)
2.	Ossenkoppele, Gert: 2 articles (02/2021 - 04/2014)
3.	Allbritton, Nancy L: 2 articles (02/2014 - 05/2013)
4.	Kovarik, Michelle L: 2 articles (02/2014 - 05/2013)
5.	Krige, David: 2 articles (05/2011 - 08/2008)
6.	Flores, Nicolas: 2 articles (10/2010 - 08/2008)
7.	Hooftman, Leon: 2 articles (10/2010 - 08/2009)
8.	A Heckman, Caroline: 1 article (06/2022)
9.	A Holstein, Sarah: 1 article (06/2022)
10.	E Davies, Faith: 1 article (06/2022)

Related Diseases

1.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/01/2012 - "Efficacy of tosedostat, a novel, oral agent for elderly patients with relapsed or refractory acute myeloid leukemia: a review of the Phase II OPAL trial." 02/01/2014 - "Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia." 04/01/2012 - "This commentary discusses the background and results of an ongoing Phase II evaluation of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia. " 10/01/2010 - "In phase II, the therapeutic activity of the maximum-acceptable dose (MAD) of tosedostat was evaluated in elderly and/or relapsing patients with acute myeloid leukemia (AML) or myelodysplastic syndrome. " 02/01/2014 - "In this work, we examined the response of 678 individual U937 (human acute myeloid leukemia) cells to an aminopeptidase-inhibiting chemotherapeutic drug (Tosedostat) over the course of 95 days. "
2.	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/01/2021 - "Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy." 10/01/2010 - "In phase II, the therapeutic activity of the maximum-acceptable dose (MAD) of tosedostat was evaluated in elderly and/or relapsing patients with acute myeloid leukemia (AML) or myelodysplastic syndrome. " 04/01/2013 - "Additional studies of tosedostat including combination with hypomethylating agents and low-dose cytarabine in patients with high-risk myelodysplastic syndromes and AML are ongoing or planned. " 01/01/2016 - "We performed a Phase II trial to determine rates of complete remission (CR) and survival using tosedostat with cytarabine or decitabine in older patients with untreated acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). "
3.	Neoplasms (Cancer) 10/27/2020 - "Tosedostat is an orally administered metalloenzyme inhibitor with antiproliferative and antiangiogenic activity against hematological and solid human cancers. " 09/01/2015 - "To our knowledge, the effective combination of CHR-2797 with radiation exposure has not been reported previously in any cancer cell type. " 01/01/2019 - "Tosedostat is an inhibitor of aminopeptidases currently in phase II clinical trials for the treatment of blood-related cancers. " 01/01/2022 - "While there are agents that directly target aminopeptidases that demonstrate potential as cancer therapies, such as bestatin and tosedostat, more selective and more targeted therapeutic approaches are needed. " 08/01/2009 - "A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors."
4.	Adenocarcinoma 02/01/2020 - "Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinoma."
5.	Leukemia 04/01/2012 - "Tosedostat is an orally available aminopeptidase inhibitor shown to have activity in leukemia. " 08/15/2008 - "Gene expression microarrays were used to profile changes in mRNA expression levels in the human promyelocytic leukemia cell line HL-60 treated with CHR-2797. "

Related Drugs and Biologics

1.	Cytarabine (Cytosar-U)
2.	Decitabine
3.	tosedostat
4.	Aminopeptidases
5.	Prodrugs
6.	Capecitabine (Xeloda)
7.	Vaccines
8.	Sodium
9.	Proteins (Proteins, Gene)
10.	Gefitinib (Iressa)

Related Therapies and Procedures

1.	Therapeutics
2.	Stents
3.	Radiotherapy